Chen Xing, Ma Xiao, Wang Ruilin, Wang Lifu, Li Jianyu, Liu Honghong, He Tingting, Wei Shizhang, Li Haotian, Wang Min, Zhao Yanling
Department of Pharmacy, Chinese PLA General Hospital, Beijing.
College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu.
Medicine (Baltimore). 2020 Nov 13;99(46):e23107. doi: 10.1097/MD.0000000000023107.
Ursodeoxycholic acid is the priority drug of primary biliary cirrhosis (PBC) and is usually combined with traditional Chinese medicine. This study aimed to systematically evaluate the benefits of integrated Chinese and western interventions for PBC.
Searched the randomized controlled trials in PubMed, Web of Science, CNKI, CBM, Wanfang, VIP databases. The Cochrane risk of bias tool was used for methodological quality assessment and all data analysis was performed using Revman5.3 and Stata14.2 software.
30 randomized controlled trials involving 10 interventions with a total of 1948 participants were included. Identified the direct and indirect evidence of trials, and used network meta analyses ranked the benefits of different interventions based on pairwise meta analysis. The primary outcom was clinical efficacy rate. Secondary outcome was liver function, including alkaline phosphataseand total bilirubin.
The conclusion of this systematic review provide credible evidence - based for the relative advantages of integrated Chinese and western interventions for PBC.
熊去氧胆酸是原发性胆汁性肝硬化（PBC）的首选药物，通常与中药联合使用。本研究旨在系统评价中西医结合干预PBC的疗效。
检索PubMed、Web of Science、CNKI、CBM、万方、维普数据库中的随机对照试验。采用Cochrane偏倚风险工具进行方法学质量评估，所有数据分析均使用Revman5.3和Stata14.2软件进行。
纳入30项随机对照试验，涉及10种干预措施，共1948名参与者。识别试验的直接和间接证据，并基于成对荟萃分析使用网络荟萃分析对不同干预措施的疗效进行排序。主要结局为临床有效率。次要结局为肝功能，包括碱性磷酸酶和总胆红素。
本系统评价的结论为中西医结合干预PBC的相对优势提供了可靠的循证依据。
